Scinai Immunotherapeutics News and Resources

Scinai Immunotherapeutics Ltd., a biopharmaceutical company focused on inflammation and immunology (I&I) biological products and contract manufacturing, has signed a binding option agreement to acquire Italian biotech firm Pincell srl. The agreement aligns with Scinai’s strategy to advance novel therapies

Scinai Immunotherapeutics has announced a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., a fund managed by Yorkville Advisors Global, LP. The agreement grants Scinai the right, but not the obligation, to sell up to $10 million in American Depository

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) has announced the establishment of a U.S.-based subsidiary, Scinai Bioservices Inc., incorporated in Delaware. The new unit will focus on providing contract development and manufacturing (CDMO) services to early-stage biotech companies, addressing a critical gap